Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
West China School of Medicine, Sichuan University, Chengdu, Sichuan, 610041, China.
Ann Hematol. 2024 Oct;103(10):4211-4222. doi: 10.1007/s00277-024-05688-x. Epub 2024 Mar 9.
Histological transformation into an aggressive B-cell lymphoma indicates a poor survival outcome for patients with indolent marginal zone lymphoma (MZL), which has been less studied. Large-scale data with long-term follow-up to investigate MZL transformation is limited. Here, by reporting a US-Nationwide cohort of 30,619 MZL patients diagnosed between 2000 and 2019, we found that transformation occurred in 2.08% (N = 624) of MZL cases, with the transformation incidence of 3.1 per 1,000 person-years. Advanced Ann Arbor stage, nodal MZL (NMZL) and splenic MZL (SMZL) were associated with an elevated risk of transformation. Certain subtype-specific characteristics, such as non-gastric extra-nodal MZL (vs. gastric, HR, 1.51, 95%CI 1.13-2.04; p = 0.006), and receiving splenectomy for SMZL (HR, 2.04, 95%CI 1.28-3.26; p = 0.003), also indicated a higher risk of transformation. Besides, transformation independently increased the overall mortality risk (HR, 1.38, 95%CI 1.24-1.53, p < 0.001), especially the higher lymphoma-caused mortality risk (HR, 3.21, 95%CI 2.81-3.67, p < 0.001). Transformation was also associated with a higher percentage of lymphoma-caused deaths. The post-transformation prognostic analyses demonstrated that female gender and age ≥ 65 years independently affected patients' mortalities. These findings, based on the largest cohort to date, contribute to a better understanding of transformed MZL, and provide valuable reference points for guidelines and patient counseling.
惰性边缘区淋巴瘤(MZL)发生侵袭性 B 细胞淋巴瘤转化预示着患者生存结局较差,然而目前对其研究较少。缺乏针对 MZL 转化的大规模、长期随访的大型数据。在此,我们通过报告一项美国全国范围内的 30619 例 2000 年至 2019 年间诊断为 MZL 的患者队列,发现有 2.08%(N=624)的 MZL 病例发生转化,每 1000 人年有 3.1 例转化。晚期 Ann Arbor 分期、结外边缘区淋巴瘤(NMZL)和脾边缘区淋巴瘤(SMZL)与转化风险增加相关。某些亚型特异性特征,如非胃结外边缘区淋巴瘤(与胃边缘区淋巴瘤相比,HR,1.51,95%CI 1.13-2.04;p=0.006)和因 SMZL 而行脾切除术(HR,2.04,95%CI 1.28-3.26;p=0.003),也提示转化风险更高。此外,转化独立增加了总死亡率风险(HR,1.38,95%CI 1.24-1.53,p<0.001),特别是淋巴瘤导致的死亡率风险(HR,3.21,95%CI 2.81-3.67,p<0.001)。转化也与更高比例的淋巴瘤导致的死亡相关。转化后的预后分析表明,女性和年龄≥65 岁独立影响患者的死亡率。这些基于迄今为止最大队列的研究结果,有助于更好地了解转化性 MZL,并为指南和患者咨询提供有价值的参考点。